Navigation Links
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Date:1/29/2009

loyees," said Thomas B. King, Alexza President and CEO. "We are extremely grateful to all of our employees for their significant contributions and efforts to create new products with a new technology, which we believe have the potential to change the practice of medicine."

"We announced last October that we were significantly ahead of schedule with AZ-004, and at the same time, we would be prioritizing and focusing on what we believe are key near-term value-drivers in 2009, being critically aware of the very difficult capital markets," Mr. King continued. "Alexza has made substantial progress with its Staccato technology and product candidates over the past several years, but find our industry faced with an intensely difficult funding environment, which is critical to the growth of life science companies. The difficult choices we are making reflect that reality, even in the face of our own internal successes."

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive initial results from both of its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application submission in early 2010. The Company has compl
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
9. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
10. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
11. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... Rochelle, Virginia (PRWEB) August 23, 2014 ... of NDA Partners LLC announced today that Janet ... a Premier Expert consultant. NDA Partners Premier Experts ... stature enable them to bring extraordinary value to ... and implement critical solutions to help clients successfully ...
(Date:8/22/2014)... August 23, 2014 This is ... state of the Papain industry in Global and ... the industry, including definitions, applications and industry chain ... analysis are provided with a focus on history, ... A comparison between the international and Chinese situation ...
(Date:8/22/2014)... Muncie, IN (PRWEB) August 22, 2014 Today ... Review in the United States Court of Appeals for the ... for Model Aircraft published in the Federal Register on June ... Interpretive Rule is contrary to the text and intent of ... 112-95, and violates Congress’ specific prohibition on any new rules ...
(Date:8/22/2014)... Aug. 22, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... ended June 30, 2014.  Biorem,s complete 2014 second quarter financial statements and ... Summary:Three-months ended June 30, , Six-months ended June ... , 2013 , 2014 , 2013 ... , 9,195 Gross profit , 56 , ...
Breaking Biology Technology:Noted Epidemiologist and Former FDA Deputy Director Janet B. Arrowsmith, MD, Joins NDA Partners as a Premier Expert Consultant 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3
... Iceland, and ALAMEDA, California, April 23, deCODE genetics ... CRA ) today announced the signing of agreements ... to deCODE,s,genetic markers for increased risk of major ... fibrillation (AF) and type 2,diabetes (T2D). These markers ...
... April 23 Cord Blood America, Inc. (OTC Bulletin ... company ( http://www.cordblood-america.com ) focused ... to families nationwide and internationally, which recently announced it ... said today it has eliminated another $817,000 of long-term ...
... honors President Carter, Carter Center for fight against neglected ... Progress (GHP) and ONE, as well as members of ... foundations and the business community, welcomed a delegation of ... reception on Capitol Hill today. The delegation presented a ...
Cached Biology Technology:deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes 2deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes 3deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes 4deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes 5deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes 6deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes 7Cord Blood America Further Reduction, $817,000, in Long-Term Debt 2African Health Delegates Welcomed to Washington 2
(Date:8/22/2014)... , August 22, 2014 ... ) has announced the addition of ... 2014-2018"  report to their offering.  ... ,Biometrics is a technology that helps ... on their physical or behavioral features. ...
(Date:8/22/2014)... a leading source of information for businesses and professionals, ... Riverside in its 2014 list of "some of the ... generate the list, the company analyzed citation data over ... has had enormous impact. , The following UC Riverside ... the greatest number of highly cited papers in one ...
(Date:8/22/2014)... at the 29th Annual International Papillomavirus Conference shows ... Inc. combats three types of human papillomavirus, including ... cervical cancer. , When tested in several cultured ... HPV-16, HPV-18 and HPV-11 cells, according to Louise ... presented the findings at the Seattle conference. The ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... filled with widespread species, while moderate and higher elevations were ... is turning out to be partially incorrect. Widespread species now ... new study describes four species once considered to be the ... Plica plica . The study was published in ...
... researchers found that chicken eggs can provide a better ... professor in Clemson,s College of Agriculture, Forestry and Life ... Research Excellence award that allowed researchers to identify two ... congenital deafness and spine deformities in humans. Chapman ...
... turns out that your messenger RNA may catch more than one ... mRNA may travel one way down a cell, then board another, ... get where it ultimately needs to be. It,s a ... differentiating a brain cell from, say, a muscle cell, said ...
Cached Biology News:The collared treerunner is more than a single species 2Clemson research finds chickens offer clues to human birth defects 22-way traffic enable proteins to get where needed, avoid disease 2